&w=3840&q=100)
Cordelia Cruise owner files DRHP, Biocon launches ₹4,500-crore QIP, more
The IPO proceeds will be used for payment of deposit/advanced lease rental and monthly lease payments to its step-down subsidiary, Baycruise Shipping.
Waterways Leisure Tourism currently operates a cruise vessel, the MV Empress, under the brand name Cordelia Cruises, and since its launch, 549,051 guests have sailed on its cruise vessel, which has covered more than 2,25,079.53 nautical miles along the Indian coastline and surrounding islands as of December 31, 2024.
The firm's cruise vessel primarily sails to domestic destinations, including Mumbai, Goa, Kochi, Chennai, Lakshadweep, Visakhapatnam and Puducherry. It also offers international itineraries, including Hambantota, Trincomalee and Jaffna.
Centrum Capital, Intensive Fiscal Services and Motilal Oswal Investment Advisors are the book-running lead managers.
Biocon launches ₹4,500-cr QIP
Biocon has launched a qualified institutions placement (QIP) to raise ₹4,500 crore. The biopharmaceutical firm will issue up to 139 million new shares — 11.6 per cent of the current outstanding equity base. The floor price for the QIP has been set at ₹323.2. Shares of Biocon last closed at ₹357.3, valuing the firm at ₹42,900 crore. The issuance price will be finalised on Thursday, while trading in the new shares will commence from Tuesday.
Biocon will use the QIP proceeds to purchase outstanding optionally convertible debentures issued by subsidiary Biocon Biologics. It will also use the proceeds to repay outstanding debt and for general corporate purposes. BofA Securities, Kotak Mahindra and Goldman Sachs are the investment bankers handling the share sale.
IFC commits $60 mn to Motilal Oswal Alternates
The International Finance Corporation (IFC), a member of the World Bank Group, has signed an agreement to invest $60 million in Motilal Oswal Alternates' India Business Excellence Fund V G (IBEF VG), with an additional $60 million co-investment envelope.
The fund, targeting $750 million (with a $150 million green-shoe option), will support 12–16 mid-market companies in consumer, financial services, life sciences and manufacturing sectors, focusing on expansion, job creation and technology adoption, particularly in India's Tier-II and Tier-III cities.
Managed by MO Alternates, the private investment arm of Motilal Oswal Financial Services Ltd, IBEF VG aims to bridge the funding gap for small and medium enterprises (SMEs) in underserved regions. IFC will also support the fund in enhancing women's workforce participation through workshops and standards.
NSE IX inks MoU with Cyprus Stock Exchange
The NSE International Exchange (NSE IX), based in GIFT City, has signed a Memorandum of Understanding (MoU) with the Cyprus Stock Exchange (CSE). The agreement was formalised during a roundtable event held in Limassol, Cyprus, during the official visit of India's Prime Minister Narendra Modi and attended by President of the Republic of Cyprus, Nikos Christodoulides.
The MoU establishes a framework for multifaceted collaboration between NSE IX and CSE, focusing on cross and dual listings of financial instruments, joint development of innovative financial products, knowledge and research collaboration, capacity-building initiatives and fintech engagement programmes.
PM Modi said: 'I am pleased to know that the Cyprus Stock Exchange and NSE have agreed to collaborate in Gujarat's GIFT City.'
RIL sells another 0.89% stake in Asian Paints
Siddhant Commercials, a subsidiary of Reliance Industries (RIL) on Monday, sold another 0.89 per cent stake in Asian Paints via block deals. The RIL entity sold 8.5 million shares at Rs 2,207 apiece to ICICI Prudential Mutual Fund for Rs 1,876 crore. Last week, it had sold 35 million shares (3.6 per cent equity) at Rs 2,201 apiece to SBI Mutual Fund for Rs 7,704 crore. At the end of March 2025 quarter, Siddhant held 4.9 per cent stake (47 million shares) of the paints major.
AlphaGrep Securities gets in-principle approval for MF foray
AlphaGrep Securities, a quantitative investment firm specialising in systematic strategies, has received in-principle approval from the Securities and Exchange Board of India (Sebi) to foray into mutual funds (MFs). AlphaGrep Investment Management (AGIM), the asset management vertical of the financial services firm, will house the proposed MF business. AGIM has an AUM of over Rs 2000 crore and 500+ clients across two CAT III AIFs (long-short), Long Only PMS and GIFT City-domiciled outbound CAT III AIF, the company said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
22 minutes ago
- Economic Times
Nithin Kamath slams flawed comparison between India and US in candid post, says ‘Gambling runs deep in American culture'. Netizens applaud
Agencies Zerodha's Nithin Kamath sparked debate by contrasting India's options trading with the US, cautioning against superficial comparisons. He emphasized that India's market is less leveraged and still developing, unlike the US, which he characterized as having a deep-rooted gambling culture. In a bold and unfiltered post that's making waves across financial circles, Zerodha co-founder Nithin Kamath has challenged what he calls a 'misguided narrative' comparing India's options trading volumes to those of the United States. And he isn't mincing words. Kamath took to social media this week, highlighting stark contrasts in market maturity, investor behavior, and cultural ethos—concluding with a punchline that's hard to ignore: 'Gambling runs deep in American culture.' The remarks, which appear in a now widely circulated LinkedIn post, reflect growing concerns over surface-level interpretations of trading data, especially as India's retail participation in stock markets continues to surge. At the heart of Kamath's argument is the assertion that Indian markets are not dangerously overleveraged, as some analysts and commentators suggest. He notes that most comparisons rely on the sheer number of options contracts traded, without factoring in premiums or actual capital value. 'If anything, India is significantly less leveraged than the US, even taking into account the fact that our markets are 15–20 years behind theirs,' Kamath wrote in his post. To drive home the scale of difference, Kamath pointed out that the margin funding market in the US recently crossed $1 trillion. In India? It's still under $10 billion—just 1% of that. Likewise, while shorting is a trillion-dollar mechanism in the US, India's stock lending and borrowing market remains in its infancy. — Nithin0dha (@Nithin0dha) Kamath's most eyebrow-raising observation, however, came from outside the trading world—sort of. Referring to a bizarre $210 million wager on whether Ukrainian President Volodymyr Zelensky would wear a suit to the NATO summit, Kamath underlined how deeply embedded gambling is in the American psyche. 'From the stock market to sports, casinos, events, lotteries, prediction markets, and crypto, you can bet on anything,' he said. 'Calling the US a gambling society wouldn't be unfair.' Kamath's comments have ignited a spirited conversation online, with many users rallying behind his take. One user wrote, 'We actually cannot compare Indian markets with the US… the biggest companies in the US are still growing fast, but fractional investing will change the Indian market.' Another comment struck an optimistic tone: 'In the US, approximately 62% of the population has stock market investments, whereas in India, it's only 6%. India could be a sleeping giant waiting to awaken.' Other users praised Kamath for drawing attention to the importance of measuring real leverage over superficial contract counts. 'Comparing contract numbers without looking at actual value is like counting cars without checking if they're Ferraris or Fiat Puntos,' one quipped. Kamath's broader point is that while India's markets are evolving rapidly, they are still in a formative phase—and that's no reason to ring alarm bells. He argued that overzealous comparisons with mature markets like the US not only lack nuance but risk misleading retail investors and policymakers alike. 'We're still building basic infrastructure,' another netizen commented. 'Our regulators are right to be cautious given how new retail participation is. Better slow growth than 2008 crashes.' Whether one agrees or disagrees with Kamath's framing, one thing is clear: the story of India's financial markets cannot—and should not—be told through the lens of another nation's gambling habits.
Time of India
24 minutes ago
- Time of India
From stress to serenity: How India's yoga diplomacy can benefit H-1B holders
As someone who has been advocating for knowledge-worker rights since 2004, I've witnessed the H-1B visa issue evolve from online debates to kitchen table discussions and eventually, to the halls of Congress. The uncertainty and anxiety faced by Indian H-1B holders and their families have only intensified with the growing US visa backlog, now a staggering 11.3 million under the Trump administration. The US visa backlog has real-life implications for millions of Indians who have invested in their American dreams. Delays and uncertainty have become a constant source of stress, affecting not just their careers but also their personal lives. As a nation with a significant soft power asset in spiritual diplomacy, India must navigate this complex issue while balancing its strategic autonomy. A Powerful Tool for Cultural Understanding India's spiritual diplomacy, including Yoga diplomacy, can be a potent tool in promoting cultural understanding and cooperation. With International Yoga Day recognised by over 180 countries worldwide, Yoga has become a global phenomenon, promoting Indian heritage and global harmony. Yoga, with its emphasis on mindfulness, breath control, and physical well-being, can help alleviate stress and anxiety, promoting mental health and resilience. By showcasing its rich spiritual heritage and promoting Yoga, India can foster people-to-people connections and build bridges between nations. Creating a Collective Collaborative Ecosystem To harness the benefits of Yoga diplomacy, India can invite Yoga centres across the country to participate in a unified initiative. This ecosystem can be built by partnering with renowned Yoga centres and ashrams to develop and promote Yoga programs tailored to the needs of Indian citizens abroad. Digital platforms like YogaYukt can disseminate Yoga resources, including videos, apps, and online classes, to enhance accessibility and reach a wider audience of over 650,000 volunteers trained through the Yoga Certification Board. Collaborating with research institutions can also help study the benefits of Yoga and meditation for mental health and well-being. Economic Potential The significance of Yoga and Ayurveda extends beyond culture and diplomacy — they also carry major economic potential. As part of the $4 trillion global wellness industry, India has positioned itself as a leading supplier of Ayurvedic products, herbal remedies, and wellness services. Yoga-related tourism, teacher training programs, and international workshops generate revenue and open up employment opportunities. With global trends shifting toward preventive health and natural living, India is increasingly seen as a hub for integrative healthcare — a fusion of tradition and innovation. A Game-Changer for Global Understanding India's collective collaborative effort to promote Yoga diplomacy can be a game-changer in fostering global understanding, cooperation, and peace. By harnessing the power of Yoga and meditation, India can promote its rich spiritual heritage, build bridges between nations, and demonstrate its commitment to the well-being of individuals worldwide. This initiative can not only aid in addressing the challenges faced by Indian citizens abroad but also showcase India's unique cultural identity and promote a positive image of the nation globally. With a 25-million-strong Indian diaspora representing a powerful network of influence across the world, Yoga diplomacy provides a cultural link that strengthens ties between these communities and their homeland. As India continues to navigate complex global issues, its Yoga diplomacy effort can serve as a beacon of hope and cooperation, promoting a more harmonious and peaceful world order. Facebook Twitter Linkedin Email Disclaimer Views expressed above are the author's own.
Economic Times
24 minutes ago
- Economic Times
Healthcare costs in US to shoot up following Trump tariff on Indian goods: Industry experts
Agencies Representative Image New Delhi: Healthcare costs in the US will increase following the imposition of sweeping 25 per cent tariff plus an unspecified penalty on Indian goods, experts from pharmaceuticals and medical devices industry said on Thursday. President Donald Trump on Wednesday announced the imposition of a 25 per cent tariff on all goods coming from India starting August 1, plus an unspecified penalty for buying Russian crude oil and military equipment. Profits for Indian pharmaceutical firms may decline and research and development may stagnate. However, for the medical devices sector as long as the gap between duty on China and India is over 15- 20 per cent, there are positive prospects for exports to the US, according to experts. "India isn't just a key supplier of generics to the US. We are a part of the backbone of affordable global healthcare. These duties may interrupt the smooth trade flow, inflate US drug costs, stall treatments, and put even greater pressure on American healthcare budgets," OmniActive Health Technologies Executive Chairman and MD Sanjaya Mariwala said. On the other hand, he said, "Back home, the profits for Indian pharmaceutical firms may decline, and R&D may stagnate, slowing down innovation and stalling new drug clearances." AiMeD (Association of Indian Medical Device Industry) Forum Coordinator Rajiv Nath said, "Duties impact for Indian medical devices sector has to be seen from relative competitiveness - as long as duty gap between Chinese versus Indian is over 15- 20 per cent, we have positive prospects to export to USA and even put production lines in USA." Currently Indonesia and Vietnam have lower duties by 6 per cent. So for products made there they will possibly enjoy a price competitive advantage over India, he added. Stating that clarity will come after August 12 as then duties on Chinese goods will be clear, Nath said, "They were increased to over 50 per cent but temporarily reduced to 30 per cent. If post-August duties on Chinese medical devices revert to over 50 per cent and on Indian at 25 per cent, the export prospects versus China are in our favour..." He further said, "Suffice to say that whatever is the final duty that is finally announced on medical devices, if it's at least 15-20 per cent lower than applicable duty rates by US onto China then there is a strong opportunity for Indian medical devices to increase their exports to US market, if they are able to absorb the excessive high cost of regulatory approval of USFDA for market entry and find that these costs to export are sustainable over the years." However, he said, the government of India and manufacturers will need to work to improve India's competitiveness "so that we can offset the 6 per cent disadvantage over Indonesian and Vietnam competitors". Grant Thornton Bharat Partner and Tax Controversy Management Leader Manoj Mishra pointed out that the strong language used by President Trump and ongoing investigations into drug imports mean that the risk is not over yet. "Indian pharma companies should stay prepared for possible changes, especially if sector-specific duties are introduced later. That said, these tariffs are likely to be in place only for a short period, as both countries are expected to fast-track discussions for a Bilateral Trade Agreement. A balanced and stable trade deal will be key to protecting long-term interests of the sector," he noted. Similarly, Choice Broking Equity Research Analyst- Pharma Sector, Maitri Sheth said the US remains heavily reliant on India for its pharmaceutical needs, with about 50 per cent of generic drugs sourced from India. "Given the critical nature of healthcare and already elevated healthcare costs in the US, we view the likelihood of material near-term tariffs on pharma as low," Sheth added. While the headline risk persists, the structural dependence on Indian pharma and the cost sensitivity of the US healthcare system provide a strong case against aggressive tariff action on the sector, Sheth added. Medical Technology Association of India (MTaI) Chairman Pavan Choudary said President Trump's is "troubling and seems economically shortsighted and strategically misguided".
